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Abstract
Withaferin A (WFA) is a steroidal lactone present in Withania somnifera which has been shown in vitro to bind to the
intermediate filament protein, vimentin. Based upon its affinity for vimentin, it has been proposed that WFA can be used as
an anti-tumor agent to target metastatic cells which up-regulate vimentin expression. We show that WFA treatment of
human fibroblasts rapidly reorganizes vimentin intermediate filaments (VIF) into a perinuclear aggregate. This
reorganization is dose dependent and is accompanied by a change in cell shape, decreased motility and an increase in
vimentin phosphorylation at serine-38. Furthermore, vimentin lacking cysteine-328, the proposed WFA binding site, remains
sensitive to WFA demonstrating that this site is not required for its cellular effects. Using analytical ultracentrifugation,
viscometry, electron microscopy and sedimentation assays we show that WFA has no effect on VIF assembly in vitro.
Furthermore, WFA is not specific for vimentin as it disrupts the cellular organization and induces perinuclear aggregates of
several other IF networks comprised of peripherin, neurofilament-triplet protein, and keratin. In cells co-expressing keratin IF
and VIF, the former are significantly less sensitive to WFA with respect to inducing perinuclear aggregates. The organization
of microtubules and actin/microfilaments is also affected by WFA. Microtubules become wavier and sparser and the number
of stress fibers appears to increase. Following 24 hrs of exposure to doses of WFA that alter VIF organization and motility,
cells undergo apoptosis. Lower doses of the drug do not kill cells but cause them to senesce. In light of our findings that
WFA affects multiple IF systems, which are expressed in many tissues of the body, caution is warranted in its use as an anti-
cancer agent, since it may have debilitating organism-wide effects.
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Introduction
Withaferin A (WFA) is a steroidal lactone isolated from Withania
somnifera a plant that has been used in Indian (Ayurvedic) medicine
for centuries. WFA has been employed in the treatment of a wide
range of diseases including skin disease, diabetes, arthritis, and
epilepsy [1]. Recently, it has been shown that WFA binds to and
alters the distribution of vimentin intermediate filaments (VIF) in
cultured endothelial cells [2]. Biochemical studies using tryptic
fragments and molecular modeling suggest that WFA binds
covalently to cysteine-328 in the helix termination or 2B region of
the a-helical central rod domain of vimentin [2]. Based upon these
findings, it has been proposed that WFA might be useful as an
anti-tumor agent since vimentin expression is frequently up-
regulated as cancer cells undergo the epithelial to mesenchymal
transition (EMT) associated with metastasis [3]. Thus WFA may
specifically target metastatic cancer cells [4]. This possibility has
been supported by the finding that WFA inhibits the growth of and
induces apoptosis in cells derived from several human cancers
including pancreatic carcinoma (Panc-1, MIA-PaCa2, BXPC3),
osteosarcoma (Saos-2), leukemia, and lymphoma [5–7]. WFA also
inhibits the growth and metastasis of tumors in mouse models of
soft tissue sarcoma, as well as breast and pancreatic cancer [4,7,8].
The role of WFA in decreasing the size and spread of tumors may
be related to its ability to inhibit angiogenesis [2,8,9]. However,
little is known about the specific effects of WFA on vimentin either
at the cellular or biochemical levels.
Vimentin is a member of the large family of IF proteins which
are encoded by more than seventy genes [10]. The expression of
these genes has been shown to be developmentally regulated in
a cell type- and tissue-specific manner. Intermediate filaments are
categorized into five or six types based on their amino acid
sequence homologies [11]. For example, vimentin is a type III IF
protein typically expressed in cells that originate from the
mesenchyme (fibroblasts, immune and endothelial cells). And the
types I and II IF proteins, the keratins, are typically found in
epithelial cells. Regardless of their tissue origin, the defining
feature of all IF proteins is a central highly conserved a-helical rod
domain. Within the central rod, the N-terminal 1A helix initiation
and the C-terminal 2B helix termination domains are the most
highly conserved. These domains are essential for the proper
assembly of IF proteins such as vimentin into mature 10 nm
diameter filaments. Within cells, IF proteins assemble in a series of
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vimentin, it first assembles into non-filamentous particles that
polymerize into short IF (squiggles), which in turn anneal end-to-
end to form long IF [12]. There is evidence that the regulation of
these different assembly states involves numerous kinases. These
include PKA [13], Akt [14], and Cdk1 [15] which phosphorylate
vimentin at one or more of over 40 known or potential sites, and in
some cases alter the organization and assembly state of VIF [16–
18]. Additionally, VIF interact in a complex manner with the two
other major cytoskeletal systems, microtubules and microfila-
ments. As a result the normal, dispersed organization of VIF has
been shown to be dependent on the presence of microtubules and
microtubule-based motors, the kinesins and conventional dynein
[19]. VIF also interact with actin stress fibers [20,21] via IF
associated proteins such as plectin [22,23].
It has been shown that a normal cytoplasmic organization of
VIF plays an important role in determining the shape and motility
of mesenchymal cells such as fibroblasts. For example, the
induction of vimentin expression and its assembly into VIF in
MCF7 breast epithelial cells, which normally express only keratin
IF, causes a rapid change to a mesenchymal cell shape. This shape
transition is accompanied by a dramatic increase in cell motility,
thereby mimicking the behavioral changes seen during the EMT
[24]. Furthermore, the specific role of VIF in cell motility has
recently been shown to be related to the formation and positioning
of lamellipodia at the leading edge of migrating fibroblasts [25].
Since there are no known small molecule inhibitors that
specifically interfere with IF structure and function, it is important
to determine how WFA interacts with VIF and to determine the
specificity of these interactions with respect to altering VIF
functions. This is especially important as WFA has recently been
proposed as an anti-tumor agent. Even though a number of recent
papers have reported the use of WFA as an inhibitor of VIF
function, little is known regarding the mechanisms responsible for
its effects on IF or the alterations in cell physiology that
accompany WFA treatment. In this study we investigate the
effects of short and long-term WFA treatment on VIF and its
effects on cell shape, motility and proliferation. We have also
determined the specificity of WFA for VIF by testing its affects on
other types of IF, such as those comprised of the keratins,
peripherin, and neurofilaments, as well as the microtubule and
microfilament cytoskeletal systems.
Results
Withaferin A Induces the Reorganization of Vimentin
Intermediate Filaments
The effects of withaferin A (WFA) on vimentin IF (VIF)
networks were determined in human fibroblasts (BJ-5ta) by
immunofluorescence. In controls, VIF networks extend through-
out the cytoplasm, from the nucleus to peripheral regions (Fig. 1A).
After a three-hour exposure to WFA, VIF networks retract from
the cell periphery towards the nucleus. The extent of retraction
varies with the concentration of WFA. After 3 hr in 0.5 mM WFA,
the retraction is less extensive (Fig. 1B) when compared to 1.0 mM
WFA, which causes more extensive retraction (Fig. 1C). Eighty-
two percent (8261.04%, n=315) of cells treated with 2 mM WFA
show an extensive reorganization of VIF into the perinuclear
region after 3 hr. In addition, a significant number of non-
filamentous vimentin particles and short IF or squiggles, both
precursors to long IF, are observed between the juxtanuclear
aggregates and the cell surface [12]. These latter structures which
represent normal intermediate steps in the disassembly/assembly
of mature VIF are significantly more visible following WFA
treatment. In addition, the reorganization of VIF involves several
intermediate stages of retraction seen at one and two hours
following exposure to 2 mM WFA, prior to the formation of the
large perinuclear aggregates (Fig. 1D–F). The effects of WFA
treatment are reversible following 3 hr of exposure. The normal
organization of the VIF network is gradually re-established in the
majority of cells within 6 to 9 hrs following removal of WFA from
the cell culture medium (Fig. 2 B, C). We use 2 mM WFA in BJ-5ta
cells throughout the rest of this study, unless otherwise noted, as it
has a maximal reversible impact on VIF organization over short
time periods.
Withaferin A Alters Cell Shape and Motility
Previous studies from our laboratory have demonstrated that
changes in the organization of VIF networks within fibroblasts
affect cell shape, motility and the formation of lamellipodia [24–
26]. Therefore, we determined whether the changes in VIF
organization induced by WFA treatment alter cell shape by using
form factor analysis, a measure of the roundness of a cell [27]. The
form factor of BJ-5ta fibroblasts treated with 2 mM WFA is
0.39602 (n=150) after 3 hrs, which is significantly greater than
controls (0.296.01; n=100, p,0.05). Cells treated with 0.5 mM
and 1 mM WFA also show statistically significant (p,0.05)
increases in form factor compared to controls, 0.36602 (n=57)
and 0.356.02 (n=50), respectively. These changes in form factor
demonstrate a change from the typical asymmetric elongated
shapes of fibroblasts to the more rounded shapes of epithelial cells
[24].
The effects of WFA on BJ-5ta motility were determined using
time-lapse imaging. The average rate of cell migration is
significantly slower during the first 240 min following the addition
of 2 mM WFA (0.59605 mm/min, 0.42604 mm/min, and
0.31604 mm/min and 0.29604 mm/min; after one, two, three,
and four hours, respectively; Fig. 2A) compared to control cells
(0.56606 mm/min). Upon removal of WFA after 180 min,
normal motility is re-established to pre-treatment levels within
9 hrs, which corresponds to the time of the re-establishment of
normal fibroblastic shape and normal VIF organization (Fig. 2B,
C). The decrease in the rate of motility also correlates well with the
extent of VIF network retraction towards the cell nucleus (Fig. 1D–
F).
As described above, there is evidence that WFA binds
covalently to vimentin’s only cysteine residue (cys328), which is
located in the 2B region of the central rod domain [2]. Therefore,
we reasoned that an excellent control for our experiments would
be the expression of a cysteine-null vimentin. Cysteine-328 was
converted to asparagine (vimC328N) in the vimentin cDNA. This
mutant construct was transfected into SW13-1HF5 cells which are
null for vimentin and do not express other types of cytoskeletal IF.
Within 24 hrs following transfection, the mutant protein assembles
into IF networks that are indistinguishable from those assembled
from wild-type vimentin (Fig. 3A, C). Upon incubation of these
transfected cells with 9 mM WFA (the lowest effective concentra-
tion required for control cells), the VIF network formed by
vimC328N retracts into the perinuclear region in a fashion
indistinguishable from controls, which express wild-type vimentin
(Fig. 3B, D). Unfortunately, vimC328N does not work as a control,
because it shows that the cysteine residue is not required for the
WFA-induced reorganization of VIF networks.
Withaferin A Alters the Phosphorylation State of
Vimentin IF
The phosphorylation state of VIF has been shown to affect their
assembly states, cytoplasmic organization, and their dynamic
Withaferin Alters Intermediate Filament Networks
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phosphorylated at numerous sites [17] by different kinases [18].
Since serine-38 is a target for many of these kinases, it is a useful
reporter of the phosphorylation state of VIF [18,25]. Therefore,
we determined the phosphorylation level of serine-38 before and
after WFA treatment using an antibody specific for vimentin
phosphorylated at this residue (pSer38, Fig. 4). Immunofluores-
cence shows that following treatment of BJ-5ta cells with 2 mM
WFA for 3 hrs, pSer38 staining is observed in the retracted VIF
located in the juxtanuclear region, as well as in particles and
squiggles (Fig. 4B). Control cells contained a normal appearing
distribution of VIF with both vimentin and pSer38 antibodies
(Fig. 4A). The fluorescence intensity of VIF stained with the
pSer38 antibody increased a small but statistically significant
amount in WFA treated vs. control cells (from 1.456005 in
control cells to 1.486008; SEM, n=25; p,0.05). In contrast,
quantitative immunoblotting analyses of cell extracts prepared at
30, 60 and 180 min following exposure to 2 mM WFA showed
a 2.5, 5.9, and 7.2 fold increase in vimentin phosphorylation,
respectively, during WFA treatment (Fig. 4C). The discrepancy
between the immunofluorescence and biochemical measurements
may be explained by problems inherent in quantifying microscopic
images including antibody accessibility and fixation protocol.
However, there is little doubt based on the immunoblotting data
that WFA treatment induces a significant increase in vimentin
phosphorylation which is coincident with the juxtanuclear
accumulation of VIF.
Effects of Withaferin A on the Assembly of VIF In Vitro
Our results show that cysteine-328 is not required for the WFA
induced reorganization of VIF in cells. However, in vitro studies
clearly show that WFA binds to vimentin [2]. Based upon these
findings we tested whether WFA alters any parameter of the
polymerization of wild-type vimentin into IF in vitro. First, we
analyzed the steps in assembly by sedimentation velocity
ultracentrifugation in the presence and the absence of WFA
(Fig. 5). We did this under two conditions previously demonstrated
to provide optimal starter units for subsequent filament assembly:
5 mM Tris-HCl, pH 8.4 and 2 mM Na3PO4, pH 7.5 [28]. In
both cases, neither DMSO alone nor WFA with DMSO had any
influence on the sedimentation behavior of vimentin, which
exhibited an s-value of 5.6 S (Tris-buffer) and 6.2 S (Na3PO4-
buffer).
The rate and extent of the assembly of VIF in the presence of
WFA was observed by electron microscopy of negatively stained
samples and viscometry as previously described [28]. In the
presence of up to 50 mM WFA the structure of fully assembled
VIF is not significantly altered compared to controls (compare
Fig. 6A-i and Fig. 6A-ii to Fig. 6A-iii and Fig. 6A-iv). VIF appear
uniform in length and width as observed by negative stain electron
microscopy. Some VIF occasionally show lateral annealing,
however, this effect is also seen in control samples (DMSO alone;
Fig. 6A-ii, arrows). Furthermore, this DMSO-induced change is
more obvious at higher protein concentrations. At 0.5 mg/ml
protein (Fig. 6A-iv) and 1% DMSO (data not shown) VIF more
often terminate in clump-like structures. Correspondingly, the
Figure 1. WFA treatment alters the subcellular organization of VIF. BJ-5ta cells were treated for 3 hrs (A–C and F) with DMSO alone (A),
0.5 mM WFA (B), 1 mM WFA (C), and 2 mM WFA (F). In addition, cells treated with 2 mM WFA are depicted after 1 hr (D) and 2 hrs (E) which show that
the changes in VIF organization take place gradually. Cells were fixed and processed for immunofluorescence with vimentin antibodies. Arrow:
a region depicted at higher magnification in the inset, showing non-filamentous vimentin particles and short IF or squiggles. Scale bars =10 mm.
doi:10.1371/journal.pone.0039065.g001
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only slightly altered by the addition of WFA (Fig. 6B), compatible
with the electron microscopic data. Furthermore, VIF assembly
also appears to be normal as determined by centrifugation/
pelleting assays. Both with and without WFA, ,100% of the
vimentin is found in the pellet by 15 minutes following the
initiation of assembly (Fig. 6C).
Effects of Withaferin A on Other Types of Intermediate
Filaments
Different mammalian cells express one or more types of IF
proteins. Since the proposed binding site for WFA is in a domain
that is highly conserved in all cytoskeletal IF [11], we also
determined whether WFA alters other types of IF networks.
Therefore, we treated MCF7 epithelial cells, which express only
types I and II keratin heteropolymer IF (KIF) with 1–3 mM WFA.
No effects could be detected at these concentrations for 3 hrs.
However, following treatment with 4 mM WFA for 3 hrs, the
majority of the KIF network, which normally extends to the cell
surface (Fig. 7A), retracts to form a large juxtanuclear aggregate
(Fig. 7B). This response is similar to that of VIF in BJ-5ta cells.
However, the reorganization is not as extensive as seen with VIF,
as a subpopulation of KIF remain extended toward the cell
periphery.
We also determined the effects of WFA on the type III IF
comprised of peripherin found mainly in peripheral neurons [29],
and type IV IF, containing neurofilament triplet proteins (NIF)
present in the majority of neuronal cell types [30]. Pheochromo-
cytoma cells (PC12) grown in nerve growth factor contain
networks of peripherin IF (Fig. 7C’’) and ,50% also contain
NIF (Fig. 7C’) [31]. Treatment with 1 mM WFA for 3 hr induces
the retraction of both peripherin IF and NIF to the nuclear region
(Fig. 7D). Lower concentrations of WFA do not have a significant
effect on either IF type over the same time period (not shown). The
Figure 2. WFA treatment inhibits cell motility. (A) The average speed of BJ-5ta fibroblasts was calculated before treatment (white bar), during
incubation with 2 mM WFA for 4 hrs (black bars) and after the cells were allowed to recover in fresh medium (gray bars). (B and C) Cells were treated
with 2 mM WFA for 3 hrs and then placed into fresh medium followed by fixation and processing for immunofluorescence with vimentin antibodies
after 6h rs (B) and 9 hrs (C). Scale bars =10 mm.
doi:10.1371/journal.pone.0039065.g002
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elsewhere in the cytoplasm (Fig. 7D9). Peripherin IF co-localize
with NIF in the juxtanuclear aggregates, however, numerous
peripherin structures also remain outside this cap (Fig. 7D99).
Based upon these observations it is apparent that WFA effects all
four types of cytoskeletal IF.
Insights into the Use of Withaferin A as an Anti-Cancer
Agent
Most cancers arise from epithelial cells, which in their normal
differentiated states express keratin (KIF), but not VIF. However,
vimentin expression is up-regulated in, and is indeed one of the
hallmarks of, the epithelial-mesenchymal transition (EMT) that
accompanies the transformation of pre-metastatic to metastatic
cells [3]. As a consequence, it is common for cancerous cells to
express both VIF and KIF networks during the EMT. Based upon
these findings, it has been proposed that specifically disrupting VIF
using WFA in cells undergoing the EMT might prove useful in
chemotherapy [4]. However, the proposed binding site for WFA
in vimentin is highly conserved in all cytoskeletal IF. Therefore, it
is important to determine whether WFA specifically disrupts VIF
or whether it affects other types of IF as well. Thus, we determined
the effects of WFA in human A549 lung cancer cells, which
express both KIF and VIF (Fig. 8A). Treatment with a range of
concentrations showed that after 3 hrs of exposure to 4 mM WFA,
the VIF network reorganizes into the perinuclear region (Fig. 8B9),
while KIF retain their normal distribution (Fig. 8B99). Increasing
the concentration of WFA to 6 mM induces the reorganization of
both the VIF and KIF networks in 3 hrs (Fig. 8C). To determine
whether the difference in sensitivity to WFA is attributable to
a difference in the rate of retraction between KIF and VIF we
treated the cells with 4 mM WFA for 6 hrs. Under these conditions
the extent of reorganization of both IF networks is similar to that
seen after 3 hrs (data not shown). Similar differences between VIF
and KIF sensitivity to WFA are also observed in HeLa cells (data
not shown).
We also examined the effects of long-term treatment of cells
with WFA as this would be required in cancer treatment. To this
end, BJ-5ta cells were treated with 2 mM WFA for 24 hrs.
Following this period of exposure, 76.1%63.2% of the cells die as
determined by Trypan blue exclusion. We also determined that
apoptosis is the most likely cause of cell death as 69.062.2% of the
cells treated with WFA are positive for annexin V [32]; compared
to 25.862.4% in control cells (Fig. 9A). Induction of apoptosis by
WFA is confirmed by immunoblotting for the caspase-dependent
breakdown of vimentin to a 48 kDa fragment (Fig. 9B) [33].
Cells treated with lower concentrations of WFA (0.5 mM and
1 mM) for 24 hrs remain viable and contain less extensively altered
VIF networks as indicated by a slight retraction of VIF away from
the cell periphery (compare Fig. 1A to Fig. 9C and D). Following
5 days of exposure to 0.5 mMo r1mM WFA, many cells appear
larger (compare Fig. 9 E to F, data for cell exposed to 0.5 mM not
shown), suggesting that they are senescent. In support of this, the
majority of cells are positive for senescent associated b-galactosi-
dase after exposure to 0.5 mMo r1mM WFA (93.1%62.3%,
Figure 3. Cysteine-328 is not required for the effects of WFA on VIF. SW13-1HF5 cells which are null for cytoplasmic IF, were transfected with
wild-type vimentin (A) and vimentin C328N (C). The cells were then treated for 3 hrs with DMSO (A and C) or 9 mM WFA (B and D). Scale bars
=10mm.
doi:10.1371/journal.pone.0039065.g003
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0.47%60.81% (n=655) in control cells (Fig. 9 G).
Based upon these findings, we also determined the rate of BJ-5ta
cell proliferation by monitoring the number of cells every 3 days
over a nine-day period. The rate of cell proliferation is similar
between treated cells and controls during the first 3 days of WFA
treatment at a concentration of 1.0 mM WFA. However there is
a dramatic decrease in growth rate after day 3 in the WFA treated
cells (Fig. 9F). These data show that relatively low concentrations
of WFA, that do not dramatically reorganize VIF, arrest the
growth of cells by inducing senescence.
Withaferin A Also Affects the Organization of
Microtubules and Microfilaments
Since IF interact extensively with microtubules (MT), and
actin/microfilaments (MF) [19], we determined whether WFA
alters these cytoskeletal systems. In control BJ-5ta cells, normal
arrays of MTs are seen radiating from a centrally located
microtubule-organizing center (MTOC) near the nucleus
(Fig. 10A99). Following 3 hrs of exposure to 2 mM WFA, VIF
are reorganized into a perinuclear aggregate (Fig. 10B9). There
appear to be fewer MTs at the cell center compared to controls
and these are distributed mainly toward the cell periphery. In
addition, the MTOC is not apparent in 89.2%63% (n=615) of
the cells compared to 2%61% (n=600) in controls (compare
Figs 10A99 and B99). Following WFA treatment many MTs appear
wavy, rather than straight as seen in controls (compare Fig. 10A99
and B99). Under the same conditions of WFA treatment there is an
apparent increase in the number of actin stress fibers and the
appearance of extensive ‘‘sheets’’ of actin not observed in control
cells (compare Figs 10 C99 and D99).
Figure 4. WFA treatment induces an increase in the phosphorylation of vimentin serine-38. BJ-5ta cells were treated for 3 hrs with DMSO
(A) or 2 mM (B) WFA, then fixed and double labeled with vimentin (A9 and B9) and pSer38 vimentin (A99 and B99) antibodies. Scale bars =10 mm.
Arrow: a region depicted at higher magnification in the inset showing vimentin particles stained with pSer38 vimentin antibody. (C) Whole cell lysates
of cells treated with DMSO (ctrl) or 2 mM WFA for 60 min, 120 min, and 180 min, were separated by SDS-PAGE and stained with anti-vimentin and
anti-vimentin pSer38 vimentin antibodies.
doi:10.1371/journal.pone.0039065.g004
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Withaferin A causes the redistribution of VIF in fibroblasts,
from their normal arrays extending throughout the cytoplasm, into
perinuclear aggregates. Reorganization of VIF into juxtanuclear
aggregates has also been reported in cells exposed to either
microtubule depolymerizing agents such colchicine [34], or
microtubule stabilizing drugs such as Taxol [35]. Other conditions
that induce aggregates include the expression of dominant
negative vimentin mutants [36,37] and the elevated phosphory-
lation of vimentin in response to the overexpression or microin-
jection of kinases such as PKA [38], PKC, and CaM kinase II
[39]. The loss of normal VIF organization is often accompanied by
changes in cell shape and motility. For example, micro-injection of
a mimetic peptide drives the specific disassembly of VIF and
causes fibroblasts to round up [26]. Similarly, there are changes in
cell shape and a reduction of migration when vimentin expression
is down-regulated by shRNA [24]. Based upon these and other
observations, it is not surprising that the aggregation of VIF
induced by WFA is accompanied by changes in cell shape and
motility. The effects of WFA on motility may be related to the role
that VIF have been shown to play in regulating the formation of
lamellipodia. A gradient of vimentin assembly states from non-
filamentous particles, short IF, to long IF has been observed in
moving fibroblasts [25]. Fully polymerized VIF along the cell
periphery appear to prevent the membrane from ruffling and
forming lamellipodia. In contrast, the disassembly and retraction
of these peripheral VIF induces the formation of lamellipodia.
Therefore, WFA may inhibit cell motility by disrupting the
organization of VIF that is required for normal cell locomotion.
In vitro studies suggest that WFA binds covalently to cysteine-328
[2]. However, when a mutant of vimentin lacking cysteine-328 is
expressed in cells null for vimentin, it assembles into networks
which appear normal and respond to WFA in a manner
indistinguishable from the response of wild-type VIF. Since there
is evidence that WFA binds to vimentin [2], even though this does
not appear to require cysteine-328, we tested whether WFA can
affect assembly of VIF in vitro. However we could not detect any
alteration in the assembly kinetics of vimentin nor in the formation
of their tetramer building blocks. Overall our results demonstrate
that there are no detectable changes in the polymerization of
vimentin subunits into 10 nm IF in the presence of WFA.
Although it would be interesting to determine whether WFA binds
to VIF in cells, this would require a method for labeling and
localizing this small molecule in fixed cells or in vivo. Unfortunately
this methodology is not yet available. Overall our data suggest that
WFA may interact with other factors involved in regulating IF
organization such as kinases or phosphatases. Support for this
comes from the finding that WFA treatment is associated with
a significant increase in phosphorylation of vimentin at serine-38.
This particular residue is targeted by at least seven different
protein kinases including PKA, PKC, Rho-Kinase, and Akt
[14,18]. Therefore, it is possible that the increase in phosphory-
lation of vimentin reflects a WFA-induced modulation in the
activity of one of the kinases or phosphatases that regulate the
assembly state and subcellular organization of VIF [13,38].
The changes in VIF networks in the presence of WFA are
accompanied by alterations in the organization of MT and MF.
This is not surprising as VIF and MTs have been shown to interact
either directly [40]; or indirectly via a number of factors including
the microtubule based motors, kinesin [41,42] and dynein [43];
and/or other IF and microtubule associated proteins such as
plectin [44] and MAP2 [45]. There is also evidence that actin
interacts directly with vimentin [21] and indirectly through the IF
associated protein, plectin [22]. Hence, it is clear that IF interact
with both MTs and MFs and that a perturbation of any one of
these three cytoskeletal systems leads to the disruption of the other
two systems.
In addition to VIF, WFA also alters the organization of
peripherin, keratin, and neurofilament IF. Previous studies have
demonstrated that the distribution of networks comprised of glial
fibrillary acid protein (GFAP), another type III IF, is also altered
during WFA treatment [46]. In our studies to date we have not
been able to detect obvious alterations in the organization of the
Type V IF composed of the lamins, which are exclusively localized
in the nucleus (data not shown). Therefore, WFA is not specific to
VIF but can alter a variety of cytoskeletal IF systems.
Prior to metastasis epithelial derived tumor cells undergo an
epithelial to mesenchymal transition (EMT). One of the hallmarks
of the EMT is an induction of vimentin expression [3]. In light of
this, several investigators have used WFA to selectively target cells
that express vimentin. In line with our findings that WFA inhibits
cellular migration and proliferation, WFA reduces tumor growth,
invasion, and metastasis in animal models [3,4,8]. Additionally,
since vimentin is the major IF type in endothelial cells [47] and
probably the most abundant cytoskeletal protein in these cells
(unpublished observations), it is not surprising that WFA also
inhibits angiogenesis [4,8,9]. However, in light of our finding that
WFA induces the aggregation of other types of IF that are
prevalent in many different types of tissues, a thorough examina-
tion of the ancillary effects of WFA is warranted. Support for
possible side effects comes from the finding that numerous diseases
are characterized by aggregates of IF that are frequently located in
the perinuclear region. These include amyotrophic lateral sclerosis
[48], Alzheimer’s disease [49,50], diabetes [51], and giant axonal
neuropathy [52]. Therefore, it is conceivable that treatment with
WFA may cause aggregation of IF and subsequent dysfunction of
multiple tissue types. On the other hand, our finding that different
IF types exhibit different sensitivities to WFA suggests that it may
be possible to titrate its concentration so that it primarily affects
metastatic cancer cells while not disrupting the function of normal
tissue.
Figure 5. WFA does not affect the sedimentation velocity of
vimentin. Sedimentation velocity profile of vimentin (0.15 mg/ml)
reconstituted in 5 mM Tris-HCl, pH 8.4 (dashed lines) or 2 mM NaCl,
pH 7.5 buffer (solid lines) alone (red lines), with DMSO (green lines), or
with 25 mM WFA dissolved in DMSO (blue lines). Note that the curves of
the two groups of runs are practically superimposable indicating that
DMSO and DMSO plus WFA do not have any effect on the complex
formation of vimentin oligomers.
doi:10.1371/journal.pone.0039065.g005
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Cell culture
Human BJ-5ta fibroblasts (ATCC, Manassas, VA) and A549
(ATCC, Manassas, VA) cells were maintained in DMEM
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum (FCS, HyClone, Logan, UT). SW13-1HF5 [53] cells were
grown in Leibovitz L-15 (Invitrogen, Carlsbad, CA) medium
supplemented with 10% FCS. MCF7 cells (ATCC, Manassas, VA)
were maintained in MEM (Invitrogen, Carlsbad, CA) supplemen-
ted with 10% FCS, 5 mM non-essential amino acids (Cellgro,
Manassas, VA), 1 mM sodium pyruvate (Cellgro, Manassas, VA),
and 2 mM L-glutamate (Invitrogen, Carlsbad, CA). PC12 cells
(ATCC, Manassas, VA) were maintained in DMEM with 10%
calf serum (CS, HyClone, Logan, UT) and differentiated by
changing the growth medium to DMEM supplemented with 5%
CS and 50 ng/ml nerve growth factor as previously described
[31]. All cells were grown in a humidified CO2 incubator at 37uC
as described [12].
Drugs
For cell based experiments withaferin A (WFA) was purchased
from ChromaDex (Irvine, CA) and dissolved in DMSO (Sigma,
St. Louis, MO) at a stock concentration of 10 mM. WFA was
added to culture medium at different concentrations for varying
time intervals. Controls consisted of adding DMSO to culture
medium at the same dilutions.
Figure 6. WFA has no effect on the in vitro assembly of human recombinant vimentin. (A) Recombinant human vimentin (0.2 mg/ml) was
assembled for 10 min at 37uC in (i) 50 mM NaCl; (ii) with 0.25% DMSO; (iii) with 50 mM WFA; and (iv) for 30 min with 50 mM WFA at a protein
concentration of 0.5 mg/ml. The filaments were fixed with glutaraldehyde and visualized by negative stain electron microscopy. The arrows in (ii)
indicate lateral annealing and apparent fusion of individual filaments. (scale bars, 0.2 mm). (B) Viscometric analysis of vimentin assembly in the
absence (ctrl) and presence of 50 mM WFA at 37uC in 50 mM NaCl. (C) Centrifugation assay of vimentin assembled in the absence (c) and presence of
WFA (w). VIF were assembled for the indicated times (5 to 15 min) in 160 mM NaCl then centrifuged for 5 min at 10 psi in an Airfuge. Samples were
separated by SDS-PAGE and stained with Coomassie. The position of vimentin is indicated (55 kDa).
doi:10.1371/journal.pone.0039065.g006
Figure 7. WFA affects the organization of keratin and neuron
specific IF. MCF-7 cells, which express only keratin IF, were treated for
3 hrs with DMSO (A) and 4.0 mM WFA (B; the lowest effective
concentration in these cells) and stained with pan-cytokeratin
antibodies. Differentiated PC12 cells were treated for 3 hrs with DMSO
(C) or 1.0 mM WFA (D, the lowest effective concentration for these cells),
then stained with neurofilament-M (C9 and D9)a n dp e r i p h e r i n
antibodies (C99 and D99). Scale bars =10 mm.
doi:10.1371/journal.pone.0039065.g007
Figure 8. Keratin IF are less sensitive to WFA than VIF. Human
lung cancer cells, A549, were treated for 3 hrs with DMSO [ctrl] (A),
4.0 mM WFA (B), and 6.0 mM WFA (C), followed by staining with
vimentin (A9,B 9,C 9) and pan-cytokeratin antibodies (A99,B 99,C 99). Scale
bars =10 mm.
doi:10.1371/journal.pone.0039065.g008
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Construction of wild-type vimentin expression plasmid is
described elsewhere [54]. Vimentin C328N mutant cDNA was
generated by site-directed mutagenesis (Quickchange, Stratagene,
Germany). Cells were transfected by electroporation as described
previously [55].
Antibodies
Vimentin IF were stained with either mouse monoclonal anti-
vimentin V9 (Sigma, St. Lois, MO) or in Fig. 10A and B with
chicken polyclonal anti-vimentin (Covance, Princeton, NJ). Other
antibodies used were: rat polyclonal anti-yeast a-tubulin (Sigma,
St. Louis, MO), mouse polyclonal anti-pan-cytokeratin (Sigma, St.
Louis, MO), rat monoclonal anti-pSer38 vimentin TM38 [56],
rabbit polyclonal anti-peripherin #199 [57], and mouse mono-
clonal anti-neurofilament 160 (Sigma, St. Louis, MO). Actin was
labeled by staining with phalloidin conjugated to Alexa568
(Invitrogen, Carlsbad, CA). Secondary antibodies included
Alexa488-, Alexa568- conjugated goat anti-rabbit, anti-mouse,
anti-chicken, and anti-rat IgG (Jackson ImmunoResearch, West
Grove, PA).
Immunofluorescence
Cells grown on glass coverslips were rinsed with phosphate
buffered saline (PBS) and fixed in methanol at 220uC for 5 min.
For Figure 10 C and D cells were fixed in 3.7% formaldehyde for
10 min at room temperature to preserve actin. Subsequently, the
cells were incubated with the appropriate primary antibody for
30 min at 37uC in a humidified chamber. After three washes with
PBS they were incubated with appropriate secondary antibodies
for 30 min at 37uC. The coverslips were then mounted on glass
slides in 100 mM Tris pH 9.0, 50% glycerol (v/v) containing
2 mg/ml p-phenylenediamine (Sigma, St. Louis, MO). Fluores-
cence images of fixed/stained cells were taken using a Zeiss
Confocal LSM 510 microscope equipped with a Plan-Apochromat
1.4NA 63x objective (Carl Zeiss, Jena, Germany). The cell
periphery was traced using phase contrast images and super-
imposed over fluorescent images using Adobe Photoshop CS5
(San Jose, CA). The mean fluorescence intensity was calculated by
importing images into Volocity 3D Image Analysis Software
(PerkinElmer, Waltham, MA), thresholding the image, subtracting
background pixels, and calculating the mean object intensity for
each image and channel. All scale bars are 10 mm except where
noted.
Live Cell Imaging
Time-lapse observations of live cells were made using the Nikon
Eclipse TE2000-E microscope equipped with the Perfect Focus
system (Nikon, Meliville, NY) and an INU stage incubator system
(Tokai Hit, Shizuoka-Ken, Japan). Images were captured using
a CoolSnapEZ camera (Photometrics, Tucson, AZ) at 5 min
intervals through a 10x objective.
Cell Motility Assay
The rate of cell motility was determined by tracking the position
of the center of the nucleus over time using Metamorph v7.0
(Molecular Devices, Sunnyvale, CA). The distance between the
positions were determined and divided by the interval between the
time points and then averaged. The motility of control cells was
determined for one hour in normal growth medium. Cell motility
was monitored for 4 hrs in 2 mM WFA; the medium was refreshed
and motility was monitored for an additional 16 hrs.
cells treated for 24 hrs with0.5 mM WFA (C) and1 mM WFA (D) were stained with vimentin antibodies. BJ-5ta fibroblasts were incubated with DMSO
alone (E) or 1 mM WFA (F) continuously for 5 days and stained for senescence-associated ß-galactosidase. (H) Cell proliferation of BJ-5ta cells was
monitored by counting cells every 3 days during continuous incubation with DMSO alone (black line) or 1.0 mM WFA (red line). Scale bars =10 mm.
doi:10.1371/journal.pone.0039065.g009
Figure 10. WFA also alters the organization of microtubules
and microfilaments. BJ-5ta cell were treated with DMSO (A and C)
and 2 mM WFA (B and D) for 3 hrs and stained with vimentin antibodies
(A9,B 9,C 9,D 9), tubulin antibodies (A99 and B99), and phalloidin to
visualize to actin (C99 and D99). Scale bars =10 mm.
doi:10.1371/journal.pone.0039065.g010
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For quantification of cell shape, fixed cells were imaged using
a Zeiss AxioImager.Z1 equipped with a 40x phase contrast
objective and a Zeiss AxioCam MRm camera (Carl Zeiss, Jeta,
Germany). Cell perimeter and area were determined by tracing
the cell perimeter using Zeiss AxioVision software (Carl Zeiss, Jeta,
Germany). Cell shape was expressed using form factor (FF),
4p*(area)/(perimeter) ˆ2, as described previously (Soll, 1988).
Senescence Assay
The induction of cellular senescence by treatment with WFA
was determined by staining for b-galactosidase activity according
to previously published protocols [58]. Briefly, cells grown on glass
coverslips were fixed with 3.7% formaldehyde, 0.2% glutaralde-
hyde for 10 min at room temperature. After thorough rinsing, the
cells were incubated for 4 hrs at 37uC with 50 mg/ml X-gal,
8 mM sodium citrate pH 6.0, 5 mM potassium ferrocyanide,
5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2.
Apoptosis Assay
Cells were stained for annexin V externalization using the
Annexin V Apoptosis Assay (Clontech, Mountain View, CA)
according to the manufacturer’s instructions and counted by
FACS.
Analysis of the Effects of WFA on the Assembly of
Vimentin IF In Vitro
Recombinant human vimentin, solubilized in 8 M urea, was
renatured by overnight dialysis into either 5 mM Tris-HCl
(pH 8.4) or 2 mM sodium phosphate (pH 7.5) containing 1 mM
DTT as described [28]. For analytical ultracentrifugation the
samples were dialyzed for one hour against fresh buffer without
DTT. Sedimentation velocity runs were performed exactly as
described [28]. Withaferin A (99% pure by HPLC, Enzo Life
Sciences, Farmingdale, NY) was dissolved in DMSO (20 mM) and
further diluted such that vimentin solutions contained final
concentrations of 25 mMo r5 0 mM WFA and 0.25 to 1.0%
DMSO, respectively. The drug was pre-incubated with re-natured
vimentin for 1 to 30 min at 37uC prior to initiation of assembly.
Assembly was carried out in the Tris-buffer system; it was initiated
by raising the ionic strength to 160 mM NaCl for 5 to 15 min as
indicated [28]. For viscometry, the protein concentration was
0.5 mg/ml; for electron microscopy of negatively stained samples
it was routinely 0.2 mg/ml except for the control for the
viscometric analysis where it was 0.5 mg/ml. In this case the
sample was fixed with 0.1% glutaraldehyde and diluted 1:5 with
assembly buffer before application to the grid. The extent of
assembly was controlled by centrifugation using an AirfugeH
(Beckman Coulter, Fullerton, California). The samples were spun
for 5 min at 10 psi, the supernatant removed and complemented
with half the volume of three times (3x) concentrated SDS sample
buffer; the pelleted filaments were resuspended in an equal volume
of SDS sample buffer containing 6 M urea. Samples were heated
for 3 min at 95uC and run on 10% polyacrylamide gels according
to the procedure of Laemmli.
Statistics
Quantitative results are presented as mean 6 standard de-
viation from three separate experiments. P-values were de-
termined by a two-tailed Students t-test with unequal variances.
Results were considered significant when the p-value was equal or
less than 0.05.
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